Publication | Open Access

A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma

UrologySubcutaneous Interleukin 2MedicineMelanomaMetronomic TherapyMalignant MelanomaDose Escalation StudyOncologyRadiation Oncology